We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Anticancer Agent and Radiotherapy Destroy Tumors but Protect Healthy Cells

By MedImaging International staff writers
Posted on 02 Dec 2014
Print article
Although radiation treatments have recently become much more optimized, it is still difficult to both sufficiently dose the tumor while sparing the surrounding tissue. A new anticancer drug currently under clinical development may help tackle this problem by protecting normal cells, but not the cancerous ones, from the effects of radiation. The research additionally suggests this drug may also be useful in treating accidental exposure to radiation.

“It was a stroke of luck that the drug that most effectively protected normal cells and tissues against radiation also has anticancer properties, thus potentially increasing the therapeutic index of radiation therapy,” said Ulrich Rodeck, MD, PhD, a professor of dermatology and cutaneous biology and radiation oncology at Thomas Jefferson University (Philadelphia, PA, USA) and senior author on the study, which was published November 14, 2014, in the journal Molecular Cancer Therapeutics.

Together with first author Vitali Alexeev, PhD, assistant professor, dermatology and cutaneous biology, Dr. Rodeck and colleagues evaluated five compounds that were shown to have radiation-protective properties in earlier studies. The researchers gave the mice one of the five compounds a day before and for several days after radiation treatment. A compound called RTA 408 emerged from this screen as a strong radiation protector and its effect was comparable to the only drug currently approved by the US Food and Drug Administration (FDA) for that purpose. (The approved drug, called amifostine, however, has a number of side effects including severe nausea or vomiting that make it an unappealing choice for clinicians.) Sites that are typically most vulnerable to radiation damage including the gut and blood cells in the bone marrow were both protected in mice treated with RTA 408.

Using human prostate cancer cells growing in lab mice, the researchers also showed that RTA 408 did not provide radiation protection to the cancer cells. In fact, when RTA 408 was administered by itself, without radiation, it also slowed the growth of human prostate cancer transplants in mice. In combination, it further augmented the tumor growth inhibitory effects of radiation. “It was really exciting to see,” stated Dr. Rodeck, “that combining radiation and RTA-408 more effectively inhibited tumor growth compared to using either one or the other as single treatment modalities.”

Dr. Rodeck and colleagues plan to continue to research the molecular foundations of these radiation-protective effects to better understand how precisely this compound works and how its process of action might be optimized for clinical applications. RTS 408 is currently being developed by REATA Pharmaceuticals (Irving, TX, USA) for a variety of clinical applications, including a trial currently enrolling patients for a topical form of the drug applied to patients who experience radiation dermatitis.

Related Links:

Thomas Jefferson University


Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform
LED-Based X-Ray Viewer
Dixion X-View
New
Portable X-ray Unit
AJEX140H
New
Digital Radiographic System
OMNERA 300M

Print article

Channels

Ultrasound

view channel
Image: The novel method of fighting cancer can stimulate critical cytokine secretion in T cells

Ultrasound-Directed Microbubbles Boost Immune Response Against Tumors

A significant challenge in cancer treatment is the tumor's ability to suppress the immune system, particularly by deactivating T cells that enter the tumor. Once inside, the tumor can inhibit T cells from... Read more

Nuclear Medicine

view channel
Image: PSMA-PET/CT images of an 85-year-old patient with hormone-sensitive prostate cancer (Photo courtesy of Dr. Adrien Holzgreve)

Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer Patients

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) imaging has become an essential tool in transforming the way prostate cancer is staged. Using small amounts of radioactive “tracers,”... Read more

General/Advanced Imaging

view channel
Image: Automated methods enable the analysis of PET/CT scans (left) to accurately predict tumor location and size (right) (Photo courtesy of Nature Machine Intelligence, 2024. DOI: 10.1038/s42256-024-00912-9)

Deep Learning Based Algorithms Improve Tumor Detection in PET/CT Scans

Imaging techniques are essential for cancer diagnosis, as accurately determining the location, size, and type of tumors is critical for selecting the appropriate treatment. The key imaging methods include... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.